Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
DST j. bras. doenças sex. transm ; 35jan. 31, 2023. ilus
Artigo em Inglês | LILACS | ID: biblio-1451615

RESUMO

Introduction: In 2022, many countries, such as Brazil, experienced outbreaks of mpox (formerly called monkeypox) in sexually active people with multiple sexual partners. Objective: Report cases of patients diagnosed with Mpox. Methods: Report three cases of patients diagnosed with Mpox treated at the STD Sector at Universidade Federal Fluminense. Results: We report three cases of young adult patients who spontaneously sought our STD service with wounds in the anogenital area, mouth and other parts of the body. These cases include a 28-year-old man (HIV positive) who had lesions on his penis and body, a 34-year-old man with perianal ulcers and adenopathy, and a 40-year-old man with painful ulcers on his penis. Conclusion: The article provides information on the symptoms, transmission, and prevention of mpox, highlighting the need for early detection, diagnosis, and prompt treatment to contain and prevent the spread of the disease. The cases presented in this study show all the characteristics of a sexually transmitted disease


Introdução: Em 2022, muitos países, como o Brasil, experimentaram surtos de mpox (anteriormente chamada de monkeypox) em pessoas sexualmente ativas com múltiplos parceiros sexuais. Objetivo: Relatar casos de pacientes diagnosticados com mpox. Métodos: Relatar três casos de pacientes com diagnóstico de mpox atendidos no Setor de Doenças Sexualmente Transmissíveis (DST) da Universidade Federal Fluminense (UFF). Resultados: Relatam-se três casos de pacientes adultos jovens que procuraram espontaneamente o Setor de DST da UFF com feridas na região anogenital, boca e outras partes do corpo. Esses casos incluem um homem de 28 anos (HIV positivo) que apresentava lesões no pênis e no corpo, um homem de 34 anos com úlceras perianais e adenopatia e um homem de 40 anos com úlceras dolorosas no pênis. Conclusão: O artigo fornece informações sobre os sintomas, transmissão e prevenção da mpox, destacando a necessidade de detecção precoce, diagnóstico e tratamento imediato para conter e prevenir a propagação da doença. Os casos apresentados apresentam todas as características de uma doença sexualmente transmissível.


Assuntos
Humanos , Masculino , Adulto , Infecções Sexualmente Transmissíveis/diagnóstico , Infecções Sexualmente Transmissíveis/transmissão , Varíola dos Macacos/diagnóstico , Varíola dos Macacos/transmissão
2.
Front Pharmacol ; 12: 624704, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33935717

RESUMO

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), identified for the first time in Wuhan, China, causes coronavirus disease 2019 (COVID-19), which moved from epidemic status to becoming a pandemic. Since its discovery in December 2019, there have been countless cases of mortality and morbidity due to this virus. Several compounds such as chloroquine, hydroxychloroquine, lopinavir-ritonavir, and remdesivir have been tested as potential therapies; however, no effective treatment is currently recommended by regulatory agencies. Some studies on respiratory non-enveloped viruses such as adenoviruses and rhinovirus and some respiratory enveloped viruses including human respiratory syncytial viruses, influenza A, parainfluenza, SARS-CoV, and SARS-CoV-2 have shown the antiviral activity of cardiac glycosides, correlating their effect with Na+/K+-ATPase (NKA) modulation. Cardiac glycosides are secondary metabolites used to treat patients with cardiac insufficiency because they are the most potent inotropic agents. The effects of cardiac glycosides on NKA are dependent on cell type, exposure time, and drug concentration. They may also cause blockage of Na+ and K+ ionic transport or trigger signaling pathways. The antiviral activity of cardiac glycosides is related to cell signaling activation through NKA inhibition. Nuclear factor kappa B (NFκB) seems to be an essential transcription factor for SARS-CoV-2 infection. NFκB inhibition by cardiac glycosides interferes directly with SARS-CoV-2 yield and inflammatory cytokine production. Interestingly, the antiviral effect of cardiac glycosides is associated with tyrosine kinase (Src) activation, and NFκB appears to be regulated by Src. Src is one of the main signaling targets of the NKA α-subunit, modulating other signaling factors that may also impair viral infection. These data suggest that Src-NFκB signaling modulated by NKA plays a crucial role in the inhibition of SARS-CoV-2 infection. Herein, we discuss the antiviral effects of cardiac glycosides on different respiratory viruses, SARS-CoV-2 pathology, cell signaling pathways, and NKA as a possible molecular target for the treatment of COVID-19.

3.
Expert Opin Ther Targets ; 24(1): 63-78, 2020 01.
Artigo em Inglês | MEDLINE | ID: mdl-31914351

RESUMO

Introduction: Chikungunya virus (CHIKV) is the causative agent of Chikungunya fever, a reemerging infectious disease. This disease can cause severe manifestations that persist for months or years after acute infection and alas, there are no antiviral drugs or vaccines available. Hence, the development of new therapeutic approaches is necessary.Areas covered: We review how computational tools have provided insights on CHIKV proteins and examine the advances in the development of potential and novel antiviral drugs. A literature search was performed using PubMed and ScienceDirect databases up to April 2019.Expert opinion: Computational approaches are valuable for gaining insights into CHIKV proteins and for the design of new anti-CHIKV agents. The collaboration between computational and experimental researchers should be strengthened so that new agents can be developed in a more rational manner. Computer-aided tools could assist in the discovery and development of safer and more efficacious novel antiviral agents from unexplored chemical spaces. Technological advances dictate that this is likely to emerge soon, thus boosting interest and research on CHIKV biology and drug, vaccine and diagnostics development.


Assuntos
Antivirais/farmacologia , Febre de Chikungunya/tratamento farmacológico , Desenho de Fármacos , Antivirais/efeitos adversos , Febre de Chikungunya/virologia , Vírus Chikungunya/efeitos dos fármacos , Vírus Chikungunya/isolamento & purificação , Desenvolvimento de Medicamentos , Humanos , Terapia de Alvo Molecular , Vacinas Virais/administração & dosagem
4.
J Biomol Struct Dyn ; 38(7): 2116-2127, 2020 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-31190614

RESUMO

Herpes simplex virus type 1 (HSV-1) infections affect about two-thirds of the world population, and the standard treatment consists of acyclovir (ACV) and its analogs, which interact with thymidine kinase (TK) blocking viral replication. Lately, the emergence of ACV-resistant strains has been reported, especially associated with TK mutations. In this context, ACV therapy fails against isolates encoding Y172C and Y53H/R163H TK mutants, but the molecular mechanism of drug resistance remains unclear. Thus, we examined the effects of these mutations on ACV and the cofactor ATP binding through molecular modeling approaches. We showed that Y172C prevents the anchoring of the aromatic ring of ACV through π-π stacking interactions, leading to an inversed binding mode and different interactions. On the other hand, Y53H/R163H remarkably affected the cofactor binding mode which shifted away from its binding site and also influenced the interaction network of ACV. This is likely due to the loss of polar interactions with R163 residue. Unlike what was observed in the wild-type complex, both drug and cofactor binding poses were not well positioned to allow the phosphorylation reaction which explains the resistance observed. Moreover, energy analysis corroborated the experimental data and showed lower theoretical affinity of ACV with mutant enzymes resulted from energetic loss in polar solvation in Y172C and electrostatic terms in Y53H/R163H mutant enzyme. Therefore, our study shed light on the resistance mechanism toward ACV of two mutant TKs identified in clinical HSV-1 strains and may further support the development of new anti-herpetic drugs to treat resistant infections. [Formula: see text] Communicated by Ramaswamy H. Sarma.


Assuntos
Aciclovir , Herpesvirus Humano 1 , Aciclovir/farmacologia , Antivirais/farmacologia , Farmacorresistência Viral/genética , Herpesvirus Humano 1/genética , Timidina Quinase/genética , Replicação Viral
5.
Front Microbiol ; 10: 2426, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31708898

RESUMO

Chikungunya virus (CHIKV) infection is one of the most challenging re-emergent diseases caused by a virus, and with no specific antiviral treatment it has now become a major public health concern. In this investigation, 25 blood samples were collected from patients with characteristic CHIKV symptoms and submitted to a virus isolation protocol, which detected 3 CHIKV isolates. These samples were evaluated by sequencing for the characterization of the strains and any homology to viruses circulating in Brazil during a recent outbreak. These viruses were used for the development of antiviral assays. Subsequently, the inhibitory effects of seaweed extracts on CHIKV replication were studied. The marine species of algae tested were Bryothamnion triquetrum, Caulerpa racemosa, Laurencia dendroidea, Osmundaria obtusiloba, Ulva fasciata, and Kappaphycus alvarezii, all of which are found in different countries including Brazil. The results revealed high levels of CHIKV inhibition, including extracts of O. obtusiloba with inhibition values of 1.25 µg/mL and a selectivity index of 420. Viral inhibition was dependent on the time of addition of extract of O. obtusiloba to the infected cells, with the optimal inhibition occurring up to 16 h after infection. Neuron evaluations with O. obtusiloba were performed and demonstrated low toxicity, and in infected neurons we observed high inhibitory activity in a dose-dependent manner. These results indicate that the algal extracts may be promising novel candidates for the development of therapeutic agents against CHIKV infections.

6.
DST j. bras. doenças sex. transm ; 31(2): 57-61, jun. 30, 2019.
Artigo em Inglês | LILACS | ID: biblio-1118733

RESUMO

Introduction: Since its discovery in the 1980s, the human immunodeficiency virus (HIV) has been the target of many studies. Nowadays, estimates show that 36.7 million people are infected with HIV worldwide. In Brazil, HIV infection overcomes 840 thousand people. Globally, only 53% of the HIV infected people are under antiretroviral therapy. Significant advances in antiretroviral therapy have been made since the introduction of zidovudine in 1987. Objective: To advance the discoveries of the available antivirals demonstrating their functional specificities. Methods: We performed a systematic review with a bibliographic survey in the Index Medicus/MEDLINE and PubMed databases for periodical and indexed articles, from 2013 to 2018 that reported on antiretrovirals used or not in the clinical practice. Results: Currently, there are six classes of antiretroviral drugs: nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors (FIs), entry inhibitors (CCRIs), and HIV integrase strand transfer inhibitors (INIs or INSTIs). In summary, several antiretroviral agents under development make HIV entry, reverse transcription, integration, and maturation emerging drug become targets. Conclusion: A multifaceted approach to antiretroviral therapy, using combinations of inhibitors that target different steps of the viral life cycle, has the best potential for long-term control of HIV infection.


Introdução: Desde sua descoberta na década de 1980, o vírus da imunodeficiência humana (HIV) tem sido alvo de muitos estudos. Atualmente, as estimativas mostram que 36,7 milhões de pessoas estão infectadas pelo HIV em todo o mundo. No Brasil, a infecção pelo HIV supera 840 mil pessoas. Globalmente, apenas 53% das pessoas infectadas pelo HIV estão sob terapia antirretroviral. Avanços significativos na terapia antirretroviral (TARV) foram feitos desde a introdução da zidovudina (AZT) em 1987. Objetivo: O objetivo deste estudo foi descrever a descoberta dos antivirais disponíveis atualmente, demonstrando suas especificidades funcionais. Métodos: Foi realizada uma revisão sistemática com levantamento bibliográfico nas bases de dados Index Medicus/MEDLINE e PubMed para artigos periódicos e indexados, no período de 2013 a 2018, que relataram antirretrovirais utilizados ou não na prática clínica. Resultados: Atualmente, existem seis classes de medicamentos antirretrovirais: inibidores nucleosídeos da transcriptase reversa (NRTIs), inibidores não-nucleosídeos da transcriptase reversa (NNRTIs), inibidores da protease (IPs), inibidores de fusão (FIs), inibidores de entrada (CCRIs) e transferência da cadeia da integrase do HIV inibidores (INIs ou INSTIs). Em resumo, vários agentes antirretrovirais em desenvolvimento fazem da entrada do HIV, da transcrição reversa, da integração e da maturação, alvos dos medicamentos emergentes. Conclusão: Uma abordagem multifacetada para a TAR, usando combinações de inibidores que visam diferentes etapas do ciclo de vida viral, tem o melhor potencial para o controle da infecção pelo HIV a longo prazo.


Assuntos
Humanos , Infecções por HIV , HIV , Antirretrovirais , Terapia Antirretroviral de Alta Atividade , Síndromes de Imunodeficiência , Infecções
7.
Nat Prod Commun ; 9(7): 1031-6, 2014 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-25230521

RESUMO

The present work describes more than 60 natural products from marine red seaweeds (Rhodophyta) and their antioxidant activities. The results indicate that algae belonging to the order Ceramiales, family Rhodomelaceae are the most promising as potential producers of antioxidants. This activity seems to be related to the ability to synthesize polyphenols and their derivatives, as bromophenols.


Assuntos
Antioxidantes/química , Antioxidantes/farmacologia , Produtos Biológicos/química , Produtos Biológicos/farmacologia , Rodófitas/química , Estrutura Molecular
8.
Rev. bras. farmacogn ; 22(4): 813-817, jul.-ago. 2012. ilus, tab
Artigo em Inglês | LILACS | ID: lil-640343

RESUMO

Bovine viral diarrhea virus (BVDV) is an etiologic agent that causes important economic losses in the world. It is endemic in cattle herds in most parts of the world. The purpose of this study was to evaluate the in vitro cytotoxic effect and antiviral properties of several marine natural products obtained from seaweeds: the indole alkaloid caulerpin (CAV, 1) and three diterpenes: 6-hydroxydichotoma-3,14-diene-1,17-dial (DA, 2), 10,18-diacetoxy-8-hydroxy-2,6-dolabelladiene (DB1, 3) and 8,10,18-trihydroxy-2,6-dolabelladiene (DB3, 4). The screening to evaluate the cytotoxicity of compounds did not show toxic effects to MDBK cells. The antiviral activity of the compounds was measured by the inhibition of the cytopathic effect on infected cells by plaque assay (PA) and EC50 values were calculated for CAV (EC=2,0± 5.8), DA (EC 2,8± 7.7), DB1 (EC 2,0±9.7), and DB3 (EC 2,3±7.4). Acyclovir (EC50 322± 5.9) was used in all experiments as the control standard. Although the results of the antiviral activity suggest that all compounds are promising as antiviral agents against BVDV, the Selectivity Index suggests that DB1 is the safest of the compounds tested.

9.
Nat Prod Commun ; 5(8): 1167-70, 2010 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-20839610

RESUMO

The CH2Cl2 crude extract and a fraction enriched with halogenated monoterpenes of the Brazilian red alga Plocamium brasiliense were evaluated for cytotoxicity and against the virus HSV-1. The extract showed low cytotoxicity compared with the fraction containing monoterpenes. The crude extract showed, in vitro, a high reduction of infectivity of the virus HSV-1.


Assuntos
Antivirais/farmacologia , Herpesvirus Humano 1/efeitos dos fármacos , Monoterpenos/farmacologia , Plocamium/química , Brasil
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...